{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:59:36Z","timestamp":1789171176290,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,11,28]],"date-time":"2016-11-28T00:00:00Z","timestamp":1480291200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1245\/s10434-016-5686-1","type":"journal-article","created":{"date-parts":[[2016,11,28]],"date-time":"2016-11-28T19:23:50Z","timestamp":1480361030000},"page":"914-922","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases"],"prefix":"10.1245","volume":"24","author":[{"given":"Angelo","family":"Di Giorgio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierandrea","family":"De Iaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"De Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Garofalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Daniele","family":"Pinna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio Maria","family":"Verdecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Ansaloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Macr\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Cappellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Ceriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Giorda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Biacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Vaira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Sammartino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,28]]},"reference":[{"issue":"7","key":"5686_CR1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/jso.21288","volume":"99","author":"J Sehouli","year":"2009","unstructured":"Sehouli J, Senyuva F, Fotopoulou C, Neumann U, Denkert C, Werner L, et al. Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. J Surg Oncol. 2009;99(7):424\u20137.","journal-title":"J Surg Oncol."},{"issue":"1","key":"5686_CR2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ygyno.2013.03.026","volume":"130","author":"KA Lowe","year":"2013","unstructured":"Lowe KA, Chia VM, Taylor A, et al. An international assessment of ovarian cancer incidence and mortality. Gynecol Oncol. 2013;130(1):107\u201314.","journal-title":"Gynecol Oncol."},{"issue":"1","key":"5686_CR3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","volume":"65","author":"RL Siegel","year":"2015","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5\u201329.","journal-title":"CA Cancer J Clin."},{"issue":"6","key":"5686_CR4","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"A Bois du","year":"2009","unstructured":"du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d\u2019Investigateurs Nationaux Pour les Etudes des Cancers de l\u2019Ovaire (GINECO). Cancer. 2009;115(6):1234\u201344.","journal-title":"Cancer."},{"issue":"8","key":"5686_CR5","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1097\/IGC.0b013e31826a3559","volume":"22","author":"M Luyckx","year":"2012","unstructured":"Luyckx M, Leblanc E, Filleron T, et al. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a retrospective French multicentric study. Int J Gynecol Cancer. 2012;22(8):1337\u201343.","journal-title":"Int J Gynecol Cancer."},{"issue":"12","key":"5686_CR6","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s00432-009-0667-4","volume":"135","author":"TC Chua","year":"2009","unstructured":"Chua TC, Robertson G, Liauw W, Farrell R, Yan TD, Morris DL. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol. 2009;135(12):1637\u201345.","journal-title":"J Cancer Res Clin Oncol."},{"issue":"2","key":"5686_CR7","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1053\/j.seminoncol.2008.12.002","volume":"36","author":"MM Leitao Jr","year":"2009","unstructured":"Leitao MM Jr, Chi DS. Surgical management of recurrent ovarian cancer. Semin Oncol. 2009;36(2):106\u201311.","journal-title":"Semin Oncol."},{"key":"5686_CR8","unstructured":"Foley OW, Rauh-Hain JA, del Carmen MG. Recurrent epithelial ovarian cancer: an update on treatment. Oncology. 2013;27(4):288\u201394, 298."},{"issue":"4","key":"5686_CR9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.soc.2012.07.007","volume":"21","author":"CW Helm","year":"2012","unstructured":"Helm CW. Current status and future directions of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer. Surg Oncol Clin N Am. 2012;21(4):645\u201363.","journal-title":"Surg Oncol Clin N Am."},{"issue":"12","key":"5686_CR10","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.ejso.2013.09.030","volume":"39","author":"N Bakrin","year":"2013","unstructured":"Bakrin N, Bereder JM, Decullier E, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol. 2013;39(12):1435\u201343.","journal-title":"Eur J Surg Oncol."},{"issue":"7","key":"5686_CR11","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1245\/s10434-014-3599-4","volume":"21","author":"PA Cascales-Campos","year":"2014","unstructured":"Cascales-Campos PA, Gil J, Gil E, Feliciangeli E, Gonz\u00e1lez-Gil A, Parrilla JJ, et al. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC\/IV ovarian cancer. Ann Surg Oncol. 2014;21(7):2383\u20139.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"5686_CR12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11864-013-0264-2","volume":"15","author":"RN Eskander","year":"2014","unstructured":"Eskander RN, Cripe J, Bristow RE. Intraperitoneal chemotherapy from Armstrong to HIPEC: challenges and promise. Curr Treat Options Oncol. 2014;15(1):27\u201340.","journal-title":"Curr Treat Options Oncol."},{"issue":"12","key":"5686_CR13","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.ejso.2015.08.172","volume":"41","author":"YR Huo","year":"2015","unstructured":"Huo YR, Richards A, Liauw W, Morris DL. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a\u00a0systematic review and meta-analysis. Eur J Surg Oncol. 2015;41(12):1578\u201389.","journal-title":"Eur J Surg Oncol."},{"issue":"5","key":"5686_CR14","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","volume":"22","author":"J Spiliotis","year":"2015","unstructured":"Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22(5):1570\u20135.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"5686_CR15","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejso.2015.11.006","volume":"42","author":"FC Mu\u00f1oz-Casares","year":"2016","unstructured":"Mu\u00f1oz-Casares FC, Medina-Fern\u00e1ndez FJ, Arjona-S\u00e1nchez \u00c1, et al. Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: long-term outcomes and perspectives from a high-volume center. Eur J Surg Oncol. 2016;42(2):224\u201333.","journal-title":"Eur J Surg Oncol."},{"issue":"36","key":"5686_CR16","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","volume":"27","author":"TD Yan","year":"2009","unstructured":"Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27(36):6237\u201342.","journal-title":"J Clin Oncol."},{"issue":"1","key":"5686_CR17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","volume":"28","author":"D Elias","year":"2010","unstructured":"Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28(1):63\u20138.","journal-title":"J Clin Oncol."},{"issue":"20","key":"5686_CR18","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","volume":"30","author":"TC Chua","year":"2012","unstructured":"Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449\u201356.","journal-title":"J Clin Oncol."},{"issue":"13","key":"5686_CR19","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1245\/s10434-012-2521-1","volume":"19","author":"TJ Herzog","year":"2012","unstructured":"Herzog TJ. The role of heated intraperitoneal chemotherapy (HIPEC) in ovarian cancer: hope or hoax? Ann Surg Oncol. 2012;19(13):3998\u20134000.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"5686_CR20","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ygyno.2014.11.072","volume":"136","author":"LM Chiva","year":"2015","unstructured":"Chiva LM, Gonzalez-Martin A. A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer. Gynecol Oncol. 2015;136(1):130\u20135.","journal-title":"Gynecol Oncol."},{"issue":"2","key":"5686_CR21","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ejogrb.2011.04.036","volume":"158","author":"PA Cascales-Campos","year":"2011","unstructured":"Cascales-Campos PA, Gil J, Galindo PJ, Machado F, Frutos IM, Paricio PP (2011) Heterogeneity in patients and methods. A problem for hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol. 158(2):361\u20132.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"25","key":"5686_CR22","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.2174\/138161212802002616","volume":"18","author":"S Mulier","year":"2012","unstructured":"Mulier S, Claes JP, Dierieck V, et al. Survival benefit of adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence. Curr Pharm Des. 2012;18(25):3793\u2013803.","journal-title":"Curr Pharm Des."},{"issue":"9","key":"5686_CR23","first-page":"695","volume":"29","author":"A Oseledchyk","year":"2015","unstructured":"Oseledchyk A, Zivanovic O. Intraoperative hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer. Oncology. 2015;29(9):695\u2013701.","journal-title":"Oncology"},{"issue":"3","key":"5686_CR24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ygyno.2014.04.013","volume":"133","author":"DG Mutch","year":"2014","unstructured":"Mutch DG, Prat J. 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecol Oncol. 2014;133(3):401\u20134.","journal-title":"Gynecol Oncol."},{"issue":"10","key":"5686_CR25","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1055\/s-0035-1558079","volume":"75","author":"I Meinhold-Heerlein","year":"2015","unstructured":"Meinhold-Heerlein I, Fotopoulou C, Harter P, et al. Statement by the Kommission Ovar of the AGO: The New FIGO and WHO classifications of ovarian, fallopian tube and primary peritoneal cancer. Geburtshilfe Frauenheilkd. 2015;75(10):1021\u20137.","journal-title":"Geburtshilfe Frauenheilkd."},{"key":"5686_CR26","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359\u201374.","journal-title":"Cancer Treat Res."},{"issue":"2","key":"5686_CR27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205\u201313.","journal-title":"Ann Surg."},{"key":"5686_CR28","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. National Cancer Institute; 2009."},{"issue":"2","key":"5686_CR29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer."},{"issue":"22","key":"5686_CR30","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","volume":"33","author":"S B\u00f6hm","year":"2015","unstructured":"B\u00f6hm S, Faruqi A, Said I, et al. Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J Clin Oncol. 2015;33(22):2457\u201363.","journal-title":"J Clin Oncol."},{"issue":"4","key":"5686_CR31","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/IGC.0b013e31821bb8aa","volume":"21","author":"M Friedlander","year":"2011","unstructured":"Friedlander M, Trimble E, Tinker A, et al. Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer. 2011;21(4):771\u20135.","journal-title":"Int J Gynecol Cancer."},{"issue":"4","key":"5686_CR32","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","volume":"17","author":"M Schemper","year":"1996","unstructured":"Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343\u20136.","journal-title":"Control Clin Trials."},{"issue":"2","key":"5686_CR33","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s13193-016-0501-9","volume":"7","author":"A Bhatt","year":"2016","unstructured":"Bhatt A, Glehen O. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer: a review. Indian J Surg Oncol. 2016;7(2):188\u201397.","journal-title":"Indian J Surg Oncol."},{"issue":"5","key":"5686_CR34","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1245\/s10434-015-5051-9","volume":"23","author":"L Chiva","year":"2016","unstructured":"Chiva L, Lapuente F, Castellanos T, Alonso S, Gonzalez-Martin A. What should we expect after a complete cytoreduction at the time of interval or primary debulking surgery in advanced ovarian cancer? Ann Surg Oncol. 2016;23(5):1666\u201373.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"5686_CR35","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2016.01.008","volume":"140","author":"JJ Mueller","year":"2016","unstructured":"Mueller JJ, Zhou QC, Iasonos A, et al. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. Gynecol Oncol. 2016;140(3):436\u201342.","journal-title":"Gynecol Oncol."},{"issue":"2","key":"5686_CR36","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ygyno.2016.03.015","volume":"141","author":"F Heitz","year":"2016","unstructured":"Heitz F, Harter P, Alesina PF, et al. Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery. Gynecol Oncol. 2016;141(2):264-70.","journal-title":"Gynecol Oncol."},{"issue":"4","key":"5686_CR37","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"M Markman","year":"2001","unstructured":"Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19(4):1001\u20137.","journal-title":"J Clin Oncol."},{"issue":"1","key":"5686_CR38","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34\u201343.","journal-title":"N Engl J Med."},{"issue":"1","key":"5686_CR39","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejogrb.2009.07.016","volume":"147","author":"JG Ferron","year":"2009","unstructured":"Ferron JG, Uzan C, Rey A, et al. Histological response is not a prognostic factor after neoadjuvant chemotherapy in advanced-stage ovarian cancer with no residual disease. Eur J Obstet Gynecol Reprod Biol. 2009;147(1):101\u20135.","journal-title":"Eur J Obstet Gynecol Reprod Biol."},{"issue":"2","key":"5686_CR40","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ygyno.2013.12.002","volume":"132","author":"Miranda V Costa da","year":"2014","unstructured":"da Costa Miranda V, de Souza F\u00eade \u00c2B, Dos Anjos CH, et al. Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: safety and effectiveness. Gynecol Oncol. 2014;132(2):287\u201391.","journal-title":"Gynecol Oncol."},{"issue":"4","key":"5686_CR41","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/annonc\/mdw007","volume":"27","author":"M Petrillo","year":"2016","unstructured":"Petrillo M, Zannoni GF, Beltrame L, et al. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies. Ann Oncol. 2016;27(4):625\u201334.","journal-title":"Ann Oncol."},{"issue":"8","key":"5686_CR42","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1245\/s10434-014-3647-0","volume":"21","author":"G Passot","year":"2014","unstructured":"Passot G, You B, Boschetti G, et al. Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosis. Ann Surg Oncol. 2014;21(8):2608\u201314.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"5686_CR43","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ygyno.2013.11.035","volume":"132","author":"CL Fag\u00f6-Olsen","year":"2014","unstructured":"Fag\u00f6-Olsen CL, Ottesen B, Kehlet H, et al. Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study. Gynecol Oncol. 2014;132(2):292\u20138.","journal-title":"A nationwide Danish study. Gynecol Oncol."},{"key":"5686_CR44","doi-asserted-by":"crossref","first-page":"153","DOI":"10.14694\/EDBK_160624","volume":"35","author":"A Leary","year":"2016","unstructured":"Leary A, Cowan R, Chi D, Kehoe S, Nankivell M. Primary surgery or neoadjuvant chemotherapy in advanced ovarian cancer: the debate continues \u2026. Am Soc Clin Oncol Educ Book. 2016;35:153\u201362.","journal-title":"Am Soc Clin Oncol Educ Book."},{"issue":"5","key":"5686_CR45","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1245\/s10434-009-0357-0","volume":"16","author":"P Harter","year":"2009","unstructured":"Harter P, Hahmann M, Lueck HJ, et al. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol. 2009;16(5):1324\u201330.","journal-title":"Ann Surg Oncol."},{"issue":"7","key":"5686_CR46","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/bjc.2011.328","volume":"105","author":"RY Zang","year":"2011","unstructured":"Zang RY, Harter P, Chi DS, et al. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer. 2011;105(7):890\u20136.","journal-title":"Br J Cancer."},{"issue":"3","key":"5686_CR47","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ygyno.2014.01.027","volume":"132","author":"P Harter","year":"2014","unstructured":"Harter P, Beutel B, Alesina PF, et al. Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer. Gynecol Oncol. 2014;132(3):537\u201341.","journal-title":"Gynecol Oncol."},{"issue":"3","key":"5686_CR48","first-page":"449","volume":"26","author":"AA Costa da","year":"2016","unstructured":"da Costa AA, Valadares CV, Mantoan H, et al. The value of secondary cytoreductive surgery in recurrent ovarian cancer and application of a prognostic score. Int J Gynecol Cancer. 2016;26(3):449\u201355.","journal-title":"Int J Gynecol Cancer."},{"issue":"2","key":"5686_CR49","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/IGC.0000000000000598","volume":"26","author":"R Laar van de","year":"2016","unstructured":"van de Laar R, Kruitwagen RF, IntHout J, Zusterzeel PL, Van Gorp T, Massuger LF. Surgery for recurrent epithelial ovarian cancer in the Netherlands: a population-based cohort study. Int J Gynecol Cancer. 2016;26(2):268\u201375.","journal-title":"Int J Gynecol Cancer."},{"issue":"3","key":"5686_CR50","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ygyno.2009.10.047","volume":"116","author":"KK Shih","year":"2010","unstructured":"Shih KK, Chi DS, Barakat RR, Leitao MM Jr. Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol. 2010;116(3):364\u20139.","journal-title":"Gynecol Oncol."},{"issue":"4","key":"5686_CR51","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1245\/s10434-012-2673-z","volume":"20","author":"C Fotopoulou","year":"2013","unstructured":"Fotopoulou C, Zang R, Gultekin M, et al. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation. Ann Surg Oncol. 2013;20(4):1348-54.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"5686_CR52","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/bjc.2012.544","volume":"108","author":"C Fotopoulou","year":"2013","unstructured":"Fotopoulou C, Savvatis K, Kosian P, et al. Quaternary cytoreductive surgery in ovarian cancer: does surgical effort still matter? Br J Cancer. 2013;108(1):32\u20138.","journal-title":"Br J Cancer."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-016-5686-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-016-5686-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-016-5686-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T04:39:47Z","timestamp":1498365587000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-016-5686-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,28]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["5686"],"URL":"https:\/\/doi.org\/10.1245\/s10434-016-5686-1","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,28]]}}}